4519N Stock Chart & Stats
$825.61
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$768.00 - $974.89
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$1.30T
Enterprise Value$13.34M
Total Cash (Recent Filing)$850.10B
Total Debt (Recent Filing)$17.51B
Price to Earnings (P/E)27.0
Beta0.74
Next Earnings
Oct 27, 2026EPS Estimate
8.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)274.78
Shares Outstanding1,679,057,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.60
Price to Book (P/B)6.70
Price to Sales (P/S)10.78
P/FCF Ratio43.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,040.41Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Exceptional ProfitabilitySustained, industry-leading margins indicate durable pricing power and operational efficiency, supporting high cash generation and reinvestment capacity. Such margins provide long-term flexibility to fund R&D, dividends and strategic investments even if top-line growth pauses.
Very Strong Balance SheetNear-zero leverage and large net cash provide structural financial resilience, reduce refinancing risk, and enable steady capital allocation (R&D, M&A, dividends). This durable strength supports long‑horizon investing and cushions policy or pricing shocks.
Robust Late‑Stage Pipeline & FilingsMultiple late‑stage successes, fast‑track designation, and a record filing cadence create a sustained pathway to new product approvals and diversified future revenue. These structural R&D outcomes reduce single‑product dependency and extend the company’s growth runway.
Bears Say
Revenue Growth VolatilityInconsistent top‑line performance reflects dependence on product cycles and one‑offs, complicating medium‑term forecasting and investment planning. Persistent volatility can strain long‑term sustaining R&D and commercial investments when new launches are delayed.
Pricing Pressure From Reimbursement & GenericsRecurrent NHI price revisions and generic entry are structural headwinds in Japan, eroding revenues for mature franchises. This risk reduces long‑term cash flows from legacy products and forces reliance on successful new launches to offset steady deflationary pricing trends.
Partner/Royalty Revenue VisibilityMaterial but timing‑uncertain royalty and profit‑share streams make earnings and cashflow less predictable. Dependence on partner commercialization timing and recognition policies can create recurring forecast risk and complicate capital allocation decisions over the medium term.
Chugai Pharmaceutical Co News
4519N FAQ
What was Chugai Pharmaceutical Co’s price range in the past 12 months?
Chugai Pharmaceutical Co lowest stock price was $768.00 and its highest was $974.89 in the past 12 months.
What is Chugai Pharmaceutical Co’s market cap?
Chugai Pharmaceutical Co’s market cap is $1.30T.
When is Chugai Pharmaceutical Co’s upcoming earnings report date?
Chugai Pharmaceutical Co’s upcoming earnings report date is Oct 27, 2026 which is in 93 days.
How were Chugai Pharmaceutical Co’s earnings last quarter?
Chugai Pharmaceutical Co released its earnings results on Jul 24, 2026. The company reported $7.357 earnings per share for the quarter, missing the consensus estimate of $8.094 by -$0.737.
Is Chugai Pharmaceutical Co overvalued?
According to Wall Street analysts Chugai Pharmaceutical Co’s price is currently Undervalued.
Does Chugai Pharmaceutical Co pay dividends?
Chugai Pharmaceutical Co does not currently pay dividends.
What is Chugai Pharmaceutical Co’s EPS estimate?
Chugai Pharmaceutical Co’s EPS estimate is 8.77.
How many shares outstanding does Chugai Pharmaceutical Co have?
Chugai Pharmaceutical Co has 1,679,057,600 shares outstanding.
What happened to Chugai Pharmaceutical Co’s price movement after its last earnings report?
Chugai Pharmaceutical Co reported an EPS of $7.357 in its last earnings report, missing expectations of $8.094. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chugai Pharmaceutical Co?
Currently, no hedge funds are holding shares in MX:4519N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
4519N Stock 12 Month Forecast
Average Price Target
$1,040.41